Patient | E/L | Disease duration (months) | Auto-antibodies | Follow-up duration (months) | FVC at baseline | FVC at the end of follow up | DLCO at baseline | DLCO at the end of follow up | Musculoskeletal involvement | Ulcers | Renal/cardiac/GI involvement | Concomitant medications |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | E | 13 | ANA | 36 | 89% | 104% | 55% | 54% | myositis | N | N/Y/Y | MTX |
2 | L | 240 | Scl70 | 36 | 101% | 113% | 52% | 61% | arthritis | Y | N/N/Y | MTX |
3 | E | 12 | ANA | 12 | 105% | 96% | 65% | 69% | N | N | N/N/Y | - |
4 | E | 24 | Scl70 | 24 | 98% | 101% | 72% | 65% | N | Y | N/N/Y | - |
5 | E | 12 | Scl70 | 18 | 100% | 113% | 56% | 43% | N | Y | N/Y/Y | - |
6 | E | 24 | Scl70 | 6 | 95% | 94% | 86% | 85% | N | Y | N/N/Y | - |
7 | E | 24 | ANA | 6 | 44% | 57% | 54% | 40% | N | Y | N/N/Y | - |
8 | E | 32 | SCL70 | 6 | 77% | 78% | 28% | 47% | N | Y | N/Y/Y | - |
9 | L | 60 | SCL70 | 6 | 115% | 115% | 54% | 62% | N | Y | N/N/Y | - |